ALFA Finder| Revenue growth | Revenue grew 5.8% YoY to ₹4,359 crore; CDMO led growth. |
|---|---|
| Margins | EBITDA margin up to 12% driven by CDMO segment profitability. |
| Demand visibility | Strong demand from large MNCs; double-digit volume growth expected in H1 FY27. |
| Management confidence | Balanced; optimistic on international CDMO but cautious on API losses. |
Growth
CDMO revenue grew 8.6% YoY; overall EBITDA margin improved to 12% from 11.2% due to operational efficiencies.
Outlook
Projected FY27 commercial supply from new Zambia facility and FY28 supply from EU-GMP plant 2.
Risks
Continued losses in API and Trade Generic segments; high raw material price volatility remains a structural headwind.
Earnings Call filed with NSE, NSE: AKUMS. Summary written with AI assistance from the document.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹768.80
- Market cap
- ₹12,100 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 33.3×Sector 43.8×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Consolidated revenue ₹1,342 Cr (+31.9% YoY) and EBITDA ₹195 Cr (+106%), led by CDMO volumes. Management gave no numeric guidance. API still loss-making and domestic branded growth is only about 8%.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has fully utilized its IPO proceeds totaling Rs. 680 Crore as of September 30, 2026. Consequently, further monitoring agency reports are no longer required.
- Value
- ₹680.0 Cr
Akums Drugs & Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27: revenue INR 1,342 cr (+31.9% YoY), EBITDA INR 195 cr (14.5% margin), PAT INR 115 cr (+168.3% YoY). CDMO-led growth; API losses narrowing.
Akums Drugs & Pharmaceuticals Results Update
Akums reported Q2 FY27 revenue of ₹1,342 crore, up 31.9%, and PAT of ₹115 crore, up 168%. The release is a press update with highlights, not the full results statement.
Akums Drugs & Pharmaceuticals Q2 FY27 Results: Net Profit ₹114.6 Cr, Up 168.4% YoY
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,342 Cr (+31.9% YoY) and net profit of ₹114.6 Cr (+168.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹114.6 Cr · +168.4% YoY
Akums Drugs & Pharmaceuticals Management Change
Akums Drugs announced the resignation of Mr. Sunil Jaiswal, SVP R&D and Senior Management Personnel, effective 31 October 2026. The resignation was submitted on 5 August 2026 citing family commitments.